Histologic Evolution of Patients With Liver Transplantation
Study Details
Study Description
Brief Summary
Certain pediatric liver transplant patients with immunosuppression levels in the therapeutic range and normal liver function tests present histological alterations (inflammation or fibrosis) in protocol biopsies.
The objective of the study was to evaluate the histological findings of protocol biopsies performed at 2, 5, 10 and 15 years after liver transplantation in pediatric patients. A follow-up biopsy is also performed 1 and 3 years after liver rejection.
To do that, a cohort study will be carried out by collecting clinical, analytical and histological data of patients undergoing post-liver transplant follow-up in pediatric hepatology and liver transplant outpatient clinics. According to the follow-up protocol for these patients, a liver biopsy is performed at 2, 5, 10 and 15 years after the transplant. In addition, ultrasound, elastography and general analysis with autoimmunity and HLA studies are carried out.
The evaluation of the histological evolution of the liver graft and its relationship with clinical and analytical changes will favor the management of immunosuppressive treatment in pediatric patients with liver transplants.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Given the increase in survival of both the graft and the transplanted patient, new questions arise regarding long-term follow-up. In general, transplant patients undergo follow-up visits that include blood tests and abdominal ultrasounds. Immunosuppression levels, graft function and possible complications (infectious, tumorous, acute or chronic rejection, renal) are monitored.
The use of immunosuppressants is mainly associated with renal, infectious complications and de novo cancer. However, insufficient levels of immunosuppression can lead to graft rejection. On the one hand, various authors have attempted to completely withdraw immunosuppressive treatment in selected patients. On the other hand, histological alterations have been evidenced in patients with normal liver function tests and who maintained serum levels of immunosuppression in the therapeutic range. The balance between these two situations in not always easy.
Hypothesis:
Certain pediatric liver transplant patients with immunosuppression levels in the therapeutic range and normal liver function tests present histological alterations (inflammation or fibrosis) in protocol biopsies.
Main objetive:
To evaluate the histological findings of protocol biopsies performed at 2, 5, 10 and 15 years after liver transplantation in pediatric patients.
STUDY PROTOCOL:
Retrospective data collection through review of medical records of pediatric liver transplant patients who meet the inclusion criteria. For the protection of personal data, the data collection form will under no circumstances contain the name or NHC, only the date of birth, weight and gender of the patient will be referenced. Each patient will be uniquely identified by an identification number (ID) that will be automatically administered by the same computer program. The correlation between the coding and the patients' personal information will be kept in written format and under lock and key in the Vall d'Hebron Hospital facilities. The demographic, clinical, analytical, ultrasound, elastographic and biopsy data of the patients will be collected. With the data collected, a database will be created that allows its analysis. The platform used to collect said data will be Certain-Li, complying with the coding requirements for patient anonymity. This is a platform developed within the framework of the international working group Graft Injury Group observing long term outcomes.
LT Follow-Up All patients received immunosuppressant treatment according to our standard protocol in accordance with current European guidelines. To monitor graft function, liver function tests were measured every 2-3 months and Doppler Ultrasound was performed annually. Liver stiffness was assessed by transient elastography (TE) using FibroScan ® (Echosens, Paris, France) with a pediatric (S) or adult (M) probe, as appropriate. TE evaluations were performed annually and whenever a follow-up biopsy was performed.
Follow-up liver biopsies Follow-up liver biopsies were obtained from patients with normal liver function tests to control histopathological changes at 2, 5, 10, and 15 years after transplantation and just before transition to adult care (aged 18 to 20 years) Diagnosis of acute liver rejection was always made by biopsy (BPAR), and rejection was graded using the Rejection Activity Index (RAI) score according to the Banff classification The fibrosis stage was assessed using the ISHAK score (0-6) in every liver biopsy
Statistical study All data collected in this registry will be provided in patient data listings. Summary tables and/or graphs will be presented for the selected parameters as appropriate to the data.
For descriptive analyses, continuous patient variables will be expressed as mean and standard deviation or median and interquartile range depending on the nature of each variable. For continuous variables, the Sudent t test for independent samples will be used, or the Mann Whitney U test when the variable does not follow a normal distribution. Fisher's exact test or the Chi-square test was used for discrete variables. The differences will be considered statistically significant with a p<0.05 (two-sided contrast). To evaluate the correlation between the follow-up time and the different variables that show liver involvement, the Pearson or Spearman coefficient will be used depending on whether or not they follow a normal distribution, respectively. The correlation coefficients will be interpreted according to the guidelines of Fleiss et al, being classified as excellent when R > 0.75, good if 0.40 ≤ R ≤ 0.75, or poor if R < 0.40. Statistical analyzes will be performed using SPSS statistical software, version 18.0 (SPSS Corporation, Chicago, IL, USA).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Chohort of pediatric Liver transplant pacients Patients under 18 years recipient of a Liver transplanbt followed in our Unit and under the follow-up liver biopsy protocol |
Other: No interventions done (obervational)
Observational study
|
Outcome Measures
Primary Outcome Measures
- Sublcinical inflamation [From 15 March 2019 to 31 december 2024]
Patients with normal liver function tests and RAI > 2 in the follow-up liver biopsy
Secondary Outcome Measures
- Fibrosis [From 15 March 2019 to 31 december 2024]
Any degree of fibrosis assessed using the ISHAK score observed in the follow-up liver biopsy
- Sublcinical inflamation modification [From 15 March 2020 to 31 december 2024]
Change in the degree of inflamation (RAI) observed between the first follow-up liver biopsy and the 1 year control (in patients with biopsy proven actute rejection)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients between 2-18 years old who have received a liver transplant at least two years ago
-
Follow-up in pediatric hepatology and liver transplant outpatient clinics at the Vall d'Hebron Hospital
-
Performing tests, ultrasound, elastography and biopsy during the last year as part of the follow-up protocol of our center
-
Patients who have signed the informed consent for inclusion in the study and the corresponding assents.
Exclusion Criteria:
-
Patients who do not meet all the inclusion criteria of the protocol.
-
Patients who are transplant recipients of multiple solid organs.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospital Universitari Vall d'Hebron | Barcelona | Catalunya | Spain | 08035 |
Sponsors and Collaborators
- Hospital Vall d'Hebron
- Spanish Society of Pediatric Gastroenterology, Hepatology and Nutrition
Investigators
- Principal Investigator: Jesus Quintero, MD, Responsible of Pediatric Hepatology and Liver Transplant Department
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PR(AMI)511/2018